FMIBlog13d
Benign Prostatic Hyperplasia (BPH) Prostate Treatment Market Set to Reach USD 47,045.80 Million by 2034 at a 3.6% of CAGR
The BPH prostate treatment market is forecasted to grow at a CAGR of 3.6%, reaching USD 47.05 billion by 2034. Growth is driven by the aging male population and increasing awareness about prostate ...
Finanznachrichten20d
Benign Prostatic Hyperplasia Surgical Treatment Market to Hit USD 17.19 Billion by 2030 with 5.3% CAGR | MarketsandMarkets
Alpha-blockers (a-blockers) are recommended as first-line treatment for BPH as it relax the smooth muscle of the prostate and bladder neck to improve urine flow and reduce bladder outlet obstruction.
Yahoo Finance20d
Benign Prostatic Hyperplasia Surgical Treatment Market to Hit USD 17.19 Billion by 2030 with 5.3% CAGR | MarketsandMarketsâ„¢
Based on drug type, the global Benign Prostatic Hyperplasia Surgical Treatment market can be divided into three segments: alpha-blockers (α-blockers), 5-alpha reductase inhibitors (5-ARIs), and ...
Medscape20d
Ramelteon Combined With an α1-blocker Decreases Nocturia in Men With Benign Prostatic Hyperplasia
We herein investigated the effects of ramelteon, an antioxidant and sleep inducer, on nocturia unresponsive to α1-blocker monotherapy in males with lower urinary tract symptoms (LUTS) as a pilot ...
Medscape22d
Alpha blocker therapy for children with dysfunctional voiding and urinary retention.
Medication was discontinued in 2 patients due to minor side effects. CONCLUSIONS: Selective alpha blocker therapy appears to be effective for improving bladder emptying in children with an ...
Yahoo Finance24d
Alpha-Synuclein Inhibitors Clinical Trial Pipeline as Novel and Extensive 22+ Therapies Likely to Enter in the Domain | DelveInsight
and others are evaluating new alpha-synuclein inhibitors drugs to improve the treatment landscape. Promising pipeline alpha-synuclein inhibitors such as Buntanetap, UCB 0599, ATH 434, ATV ...